AULRF yields 0.06% · MRK yields 2.81%● Live data
📍 MRK pulled ahead of the other in Year 1
Combined, AULRF + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AULRF + MRK for your $10,000?
AURELIUS Equity Opportunities SE & Co. KGaA is a private equity firm specializing in acquisitions, growth, complex transaction structures/carve outs, add on acquisitions, redemption of existing creditors, management buyouts, management buy-ins, P2Ps, industry consolidation, strategic acquisitions in special target industries for existing platform investments in lower middle market companies. The firm acquires, restructures and eventually sells companies in special situations including corporate spin-offs, corporate carve-outs, platform build-up succession issues, and privately held companies with issues. It seeks to invest in company spin-offs and medium-sized companies with unresolved succession, significant operational problems, and balance sheet problems due to high debt levels. The firm considers investments in private and public companies, which are primarily operating in industrial enterprises, Industrials & chemicals, information technology, business services, lifestyle, consumer goods, food and beverage, and telecoms, media, and technology (TMT). It seeks to invest in companies headquartered in Europe with the focus on European Developed Markets & Nordic region. The firm typically invests up to €250 million ($278.97 million) and between €5 ($5.6 million) and €80 million ($89.27 million) per deal in companies with sales between €30 million ($33.5 million) and €750 million ($838.54 million) and EBITDA margin from negative to more than 15 percent. In the UK, the firm invests up to £70 million ($93.5 million) in businesses with revenues between £30 million ($34.99 million) and £1000 million ($1331.14 million). It seeks to acquire majority stake, preferably 100 percent stake in underperforming businesses with development potential. The firm prefers to invest in equity. It seeks to exit its investments through sale to private, institutional or industrial investors or through an IPO. AURELIUS Equity Opportunities SE & Co. KGaA was founded on March 20, 2006, and is based in Grünwald, Germany with additional offices in Amsterdam, Netherlands; London, United Kingdom; Madrid, Spain; Milan, Italy; Munich; Germany; Stockholm, Sweden and Dusseldorf, North Rhine-Westphalia.
Full AULRF Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.